Imatinib is usually a highly effective treatment for myeloproliferative neoplasms (MPNs) associated with ABL, PDGFRA or PDGFRB gene fusions; however, occasional imatinibresponsive patients have been reported without abnormalities of these genes. To identify novel imatinib-sensitive lesions, we screened 11 BCR-ABL-negative cell lines and identified GDM1, derived from a patient with an atypical MPN (aMPN), as being responsive to imatinib. Screening of genes encoding known imatinib targets revealed an exon 12 mutation in the colonystimulating factor 1 receptor (CSF1R; c-FMS) with a predicted Y571D amino-acid substitution. CSF1R in GDM1 was constitutively phosphorylated, but rapidly dephosphorylated on exposure to imatinib. Y571D did not transform FDCP1 cells to growth factor independence, but resulted in a significantly increased colony growth compared with controls, constitutive CSF1R phosphorylation and elevated CSF1R signaling. We found that GDM1 expresses CSF1, and CSF1 neutralization partially inhibited proliferation, suggesting the importance of both autocrine and intrinsic mechanisms of CSF1R activation. An extensive screen of CSF1R in aMPNs and acute myeloid leukemia identified three additional novel missense variants. None of these variants were active in transformation assays and are therefore likely to be previously unreported rare polymorphisms or non-pathogenic passenger mutations.
Introduction
Imatinib is a small-molecule inhibitor of the ABL, ABL2, PDGFRA, PDGFRB, KIT and colony-stimulating factor 1 receptor (CSF1R) tyrosine kinases (TKs). [1] [2] [3] Treatment with imatinib has proved to be highly effective in certain leukemias, most notably chronic myeloid leukemia with the BCR-ABL fusion gene 4 and myeloproliferative neoplasms (MPNs) with gene fusions involving PDGFRA 5 or PDGFRB. 6 Response to imatinib has also been described in some MPN patients in the absence of any cytogenetic or molecular indications of sensitive gene fusions. The aim of this study was to identify novel imatinib-sensitive abnormalities, and our strategy was to screen a panel of cell lines for imatinib sensitivity, followed by a detailed mutational analysis of candidate genes.
Materials and methods

Patient samples
Samples were referred for cytogenetic and/or molecular diagnostic analysis following informed consent according to the Declaration of Helsinki. The use of residual material for research was approved by the South Wiltshire Research Ethics Committee. Referral reasons were acute myeloid leukemia (n ¼ 49) or suspected atypical MPN (aMPN) (cohort 1 ¼ 254; cohort 2 ¼ 94; Table 1 ). In addition, a cohort of 24 aMPN cases were considered to have possible imatinib-sensitive disease on the basis of results of in vitro colony and liquid-culture imatinib response assays (see below). As controls, we used anonymized DNA from healthy individuals (first-degree relatives of individuals ascertained for a variety of genetic conditions).
Cell lines
The cell lines KYO-1, GDM1, Kasumi-1, HL60, KMS-11, KMS18, MV411, NB4, NCI-H929, 697, JVM-2 and OPM-2 were grown in RPMI-1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% serum. The FDCP1 and 32D interleukin 3 (IL3)-dependent cell lines were grown in RPMI-1640 (Invitrogen) supplemented with 10% serum and 10% WEHI-3B conditioned medium as a source of IL3. The Phoenix ecotropic retroviral packaging cell line (obtained from Dr Garry Nolan, Stanford University, Stanford, CA, USA) was grown in Dulbecco's modified Eagle's medium (Invitrogen) plus 10% serum.
Cell line imatinib-sensitivity screening
Eleven BCR-ABL-negative cell linesFGDM1, Kasumi-1, HL60, KMS-11, KMS18, MV411, NB4, NCI-H929, 697, JVM-2 and OPM-2, 7 with viability above 85% by trypan blue stainingF were seeded at 2.5 Â 10 5 /ml in 25 cm 2 tissue culture flasks with the addition of 1 mM imatinib (Novartis, Basel, Switzerland). Cells were counted at a minimum of once in every 2 days. Viability of imatinib-treated cells was assessed relative to untreated controls. The BCR-ABL status of all cell lines was checked by reverse transcriptase PCR. 8 The BCR-ABL-positive cell line, KYO1, served as a positive control.
Imatinib-sensitivity screening in primary material
To identify aMPN patients with possible imatinib-sensitive disease, two imatinib-sensitivity assays were developed that are described in detail elsewhere. 9 Briefly, for the methylcellulose colony assay, peripheral blood or bone marrow mononuclear cells were seeded at 2 Â 10 5 /ml in 3 cm dishes in methylcellulose supplemented with growth factors (Stem Cell Technologies Ltd, Vancouver, Canada), cells were treated with 0, 1 and 5 mM imatinib in triplicate. Colony numbers were counted on days 7 and 14. The relative reduction in colony number in treated compared with untreated controls was used as an indicator of response by comparison with results obtained for patients with known imatinib-sensitive disease and healthy controls. For the liquid-culture assay, mononuclear cells or granulocytes were seeded in 24-well plates at 2-5 Â 10 6 /ml and treated with 0, 1 and 5 mM imatinib. Cell number was counted manually with a hemocytometer twice weekly for 2-3 weeks and medium was changed weekly. A decrease in cell number in treated vs untreated control wells indicated a positive response.
Mutational analysis of GDM1
All coding exons of PDGFRA, PDGFRB and KIT were screened by denaturing high-performance liquid chromatography as previously described. 10 Products showing aberrant peaks were sequenced with BigDye v 1.1. (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions and run on an ABI 3100 genetic analyzer. CSF1R exons 7, 12, 13, 17, 18, 21 and 22 were directly sequenced. Primer sequences are available on request.
Fusion gene screening
Fluorescent in situ hybridization for ABL and ABL2 rearrangements was performed using standard methods with bacterial artificial chromosome clones identified from the Ensembl database (www.ensembl.org). ABL bacterial artificial chromosome clones were RP11-143F18 and RP11-83J21; ABL2 bacterial artificial chromosome clones were RP11-177A2 and RP11-345I18. PDGFRA and PDGFRB were screened using a reverse transcriptase PCR test to detect specific overexpression of the kinase domain as an indicator of the presence of a fusion gene as previously described.
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Western blotting
Protein lysates were prepared as previously described, 12 fractionated using SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Immobilon; Sigma, St Louis, MO, USA). Membranes were probed with antibodies against CSF1R (sc-692; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and phospho-CSF1R (Phospho-CSF1R Y723; Cell Signaling Technology, Beverly, MA, USA).
Signals were detected using the ECL system (Amersham Biosciences, Arlington Heights, IL, USA). Where cells were stimulated with CSF1, CSF1 was added at 20 ng/ml for 5 min and then removed with several washes in medium.
CSF1 neutralization
Cells were seeded at 1 Â 10 5 /ml in 24-well dishes in RPMI-1640 with the addition of an anti-CSF1-neutralizing antibody (Abcam, Cambridge, UK) at concentrations of 0, 0.05, 0.15 and 0.5 mg/ ml. The medium was changed after 2 days and cell number was counted manually after 3 days in culture.
Amplification refractory mutation system PCR Amplification refractory mutation system primers for Y571D were designed using the primer design program available at http://cedar.genetics.soton.ac.uk/public_html/primer1.html, incorporating inner primer mismatches to enhance specific amplification. Primer sequences were outer forward, 5 0 -AAGGT CCAGGAACTGCCTGCC; outer reverse, 5 0 -CACGCACACAGG TCCCTTAAGT; inner forward (wild-type specific), 5 0 -ATCGACC CCACGCAGCTGCTTT; and inner reverse (mutant specific), 5 0 -GGGAACTCCCACTTCTCGTTATC. Products were amplified using an annealing temperature of 611C for 30 cycles and visualized on a 3% agarose gel.
Conformation-sensitive capillary electrophoresis
All coding exons of CSF1R, except exons 10 and 13, which repeatedly failed to amplify using several primer pairs, were screened by conformation-sensitive capillary electrophoresis (CSCE). Primers were designed to lie approximately 50 bp either side of the exon with an annealing temperature of 60 1C. Primer sequences are available on request. Forward and reverse M13 tag sequences were added to the gene-specific primers (5 0 -TGTA AAACGACGGCCAGT and 5 0 -CAGGAAACAGCTATGACC, respectively) to allow amplification with M13 primers of which the forward primer was FAM labeled. The PCR mixture contained ABI Amplitaq Gold PCR Master Mix plus 8% glycerol, 100 fmol/ ml gene-specific primers, 500 fmol/ml M13 primers and 2.5 ng/ml DNA template. PCR cycling conditions were 60 1C annealing temperature for 30 cycles and 55 1C annealing temperature for 10 cycles, followed by denaturation at 95 1C and a temperature fall of 0.5 1C every 20 sec for 80 cycles to allow heteroduplex formation. The products were diluted to 1:200 in water and processed on an ABI 3730 genetic analyzer. All samples Abbreviations: ARMS, amplification refractory mutation system; CML, chronic myelogenous leukemia; CSCE, conformation-sensitive capillary electrophoresis; CSF1R, colony-stimulating factor 1 receptor.
showing aberrant peaks were sequenced with BigDye v 1.1.
(Applied Biosystems) according to the manufacturer's instructions and run on an ABI 3100 genetic analyzer. For a targeted screen of CSF1R exon 12 by CSCE on cDNA, primers were designed as described above but were located within exons 11 and 13 (gene-specific primer regions: forward, 5 0 -CTTCAGC ATCTTCACAGCCACCTT; reverse, 5 0 -AGAGCTATGAGGGCAA CAGTT).
Plasmid construction
A CSF1R/VSN2 construct 13 was a gift from Dr Nick Dibb (Imperial College, London, UK). The following CSF1R mutants were created using the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA): 608C4T (R106W), 2003T4G (Y571D), 2550G4A (R753Q), 2697A4T (D802V), 3147C4T (T952I) and 3198A4T (Y969F) (numbering according to GenBank ID: NM_005211.2). Wild-type and mutant CSF1R were excised and ligated into the MINV retroviral vector. 14 
Retroviral transfections
The FDCP1 and 32D cell lines were transfected by cocultivation with the ecotropic Phoenix retroviral packaging cell line. 15 Phoenix cells were plated at 0.8 Â 10 6 per 3 cm dish and transfected the following day with CSF1R/MINV constructs using calcium phosphate. A day later, 50 000 FDCP1 or 32D cells were added per dish and cocultivated for 2 days in the presence of 2 mg/ml polybrene. Transfected cells were selected in 1 mg/ml gentamycin (Invitrogen) and expanded for 1-2 weeks before cryopreserving.
Transformation assay
Bulk cultures of FDCP1 cells, transfected with CSF1R constructs or vector control, were plated at 1 Â 10 4 /ml in 3 cm dishes in 0.3% Noble agar (Difco Laboratories, Detroit, MI, USA) in RPMI-1640 plus 10% serum and supplemented with 0.01 ng/ml murine IL3 (First Link, Birmingham, UK) and 0.5 ng/ ml human CSF1 (First Link). At day 21, colonies were fixed in situ with methanol and stained with Giemsa. Each assay was performed on at least three batches of cells transfected on different occasions.
Imatinib dose-response assay
Cells were seeded into 96-well plates at 2 Â 10 4 cells/ml in 100 ml volumes with and without imatinib. Imatinib concentrations ranged from 10 nM to 10 mM with half-log intervals. Proliferation was measured at 48 h with CellTitre 96 One Solution Cell Proliferation MTS assay (Promega, Madison, WI, USA). Absorbance was measured using an MRX Microplate Reader (Thermo Labsystems, Waltham, MA, USA). The experiment was repeated twice and results were analyzed using GraphPad Prism 4 software (GraphPad Software Inc., San Diego, CA, USA).
Results
Identification of imatinib-responsive cell lines
Eleven BCR-ABL-negative cell lines, GDM1, Kasumi-1, HL60, KMS-11, KMS18, MV411, NB4, NCI-H929, 697, JVM-2 and OPM-2, were screened for imatinib sensitivity. Two cell lines, GDM-1 and Kasumi-1, demonstrated significant sensitivity to imatinib (Figure 1 ).
Molecular cytogenetic investigation of imatinibresponsive cell lines
Following our cell line imatinib-response analysis, Kasumi-1 was reported to harbor a KIT N822L mutation 16 that is likely to account for its imatinib sensitivity. We, therefore, focused our efforts on the characterization of GDM1 and, initially, the five genes that at the time were known to encode imatinib-sensitive TKs (ABL, ABL2, KIT, PDGFRA and PDGFRB). Although the karyotype of GDM1, 48,XX,der(2)t(2;11)(q36;q13),t(6;7)(q23; q36), þ 8,del(12)(p11.2p12.2), þ 13,del(16)(q23), 17 did not suggest that any of these genes were involved, we performed fluorescent in situ hybridization initially with flanking ABL and ABL2 bacterial artificial chromosome probes and screened PDGFRA and PDGFRB with reverse transcriptase PCR to detect overexpression of the TK domains to exclude the possibility of cytogenetically cryptic gene fusions. No evidence of abnormalities of these genes was observed (data not shown), suggesting that the observed imatinib sensitivity was unlikely to be a consequence of gene fusion.
GDM1 harbors a missense CSF1R-Y571D mutation
Next, we performed mutational analysis of PDGFRA, PDGFRB and KIT; however, no abnormalities were identified. Following the identification of CSF1R as an additional imatinib target, 3 we sequenced selected exons from this gene and found a 2003T4G (GenBank ID: NM_005211.2) missense mutation within exon 12 that is predicted to result in a Y571D amino-acid change within the juxtamembrane region of the receptor. As mutations within the juxtamembrane regions of other TKs have been shown to be oncogenic, we considered Y571D to be a strong candidate for a transforming mutation.
Constitutive CSF1R phosphorylation is inhibited by imatinib
To gain additional evidence that CSF1R deregulation might underpin GDM1 imatinib sensitivity, we assessed the phosphorylation status of candidate TKs. Western blotting with antibodies against CSF1R and phospho-CSF1R demonstrated a constitutive phosphorylation of CSF1R in GDM1 that was downregulated by treatment with 1 and 5 mM imatinib (Figure 2 ). 
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CSF1-dependent FDCP1-CSF1R-Y571D cells are imatinib sensitive
FDCP1 cells are normally dependent on IL3 for their growth but can be transformed to IL3 independence by activated TKs. Transfection of FDCP1 cells with a CSF1R-Y571D expression construct did not transform cells to IL3 independence, but did permit the cells to grow in the presence of CSF1. In contrast, CSF1R-D802V, a known transforming mutant that is insensitive to imatinib, readily transformed FDCP1 cells to cytokine independence. FDCP1 cells expressing CSF1R-Y571D (grown with CSF1) and GDM1 had similar sensitivity to imatinib, with IC 50 values of 0.5-1 mM. In contrast, untransfected FDCP1 cells, grown in the presence of IL3 or expressing CSF1R-D802V in the absence of added cytokines, were imatinib resistant (IC 50 410 mM; Figure 3 ).
CSF1R-Y571D is transforming in FDCP1 cells as assessed by colony assays
Earlier studies have shown that soft agar colony growth of FDCP1 cells overexpressing mutated CSF1R in the presence of low concentrations of IL3 and CSF1 is a more sensitive transformation assay than an overt transformation to growth factor independence. 18, 19 Using this system, we confirmed the earlier reports that CSF1R-Y802V was strongly transforming compared with controls (FDCP1-expressing wild-type CSF1R or vector only), whereas CSF1R-Y969F was moderately transforming. Analysis of CSF1R-Y571D revealed that it was also moderately transforming, with colony growth slightly elevated above that of CSF1R-Y969F (Figure 4 ).
Y571D alters CSF1-stimulated activation of CSF1R
Relatively subtle TK mutants can alter the kinetics of signaling but cannot transform indicator cell lines to IL3 independence. 20 To investigate the effects of CSF1R-Y571D on signaling kinetics, we analyzed bulk cultures of 32D cells overexpressing either wild-type CSF1R or CSF1R-Y571D with and without stimulation with CSF1. We found an increased phosphorylation of CSF1R-Y571D without ligand stimulation compared with wild-type CSF1R ( Figure 5 ); after stimulation with M-CSF, wild-type CSF1R showed a peak of phosphorylation within 2-5 min after stimulation with CSF1 followed by a loss of CSF1R phosphorylation. In contrast, CSF1R-Y571D showed a reduced peak but prolonged phosphorylation after CSF1 stimulation. Activating CSF1R-Y571D in GDM1 A Chase et al
Autocrine stimulation of CSF1R in GDM1
The experiments above indicate that CSF1R-Y571D is a relatively moderate transforming mutation. Given the very strong phosphorylation of CSF1R in GDM1 and rapid dephosphorylation on imatinib treatment, we speculated that other mechanisms of receptor activation might also be involved. Reverse transcriptase PCR demonstrated the expression of CSF1, suggesting a possible autocrine mechanism for CSF1R activation (results not shown). Consistent with this hypothesis, exposure of GDM1 to a neutralizing antibody against CSF1 resulted in a reduced cell growth, which was not seen in two control cell lines EOL1 and BV173 ( Figure 6 ).
CSF1R-Y571D is rare in aMPN and acute myeloid leukemia but missense changes identified in other CSF1R exons
We were interested to determine if CSF1R mutations might be more widespread in aMPNs and, in particular, those cases that may be sensitive to imatinib. Initially, we screened all 49 acute myeloid leukemia cases and a cohort of 254 aMPN cases using a combination of CSCE on cDNA samples (195 aMPN samples) and a DNA amplification refractory mutation system PCR specific for the 2003T4G missense mutation (95 aMPN samples), but did not identify any further mutated cases. Next we undertook a CSCE screen of the CSF1R gene in a second cohort of 94 aMPN cases. Three variants were identified that were predicted to result in nonconservative amino-acid changes: 608C4T (R106W) in exon 4 in a patient with chronic myelomonocytic leukemia, 2550G4A (R753Q) in exon 17 and 3147C4T (T952I) in exon 22 in two patients with hypereosinophilia referred for FIP1L1-PDGFRA screening (numbering according to GenBank ID: NM_005211.2). No constitutional material was available to investigate whether they were acquired changes. A screen of exons 4, 17 and 22 by a combination of CSCE and sequencing in 100 healthy individuals found no further examples of the three variants. A G413S change within exon 9, identified by other groups in two idiopathic myelofibrosis samples 21 and one acute myeloid leukemia sample, 21, 22 was identified in 2/46 normal samples and could therefore be excluded as a rare nonpathogenic polymorphism.
In addition, the CSF1R gene was screened in a third cohort of patients who had shown in vitro imatinib sensitivity. One or both imatinib-sensitivity assays were successfully performed on samples from 186 patients with aMPN. Forty-four samples showed a positive response in at least one assay and a further 24 samples showed borderline responses. Seventeen of the positive samples had molecular lesions consistent with imatinib response (13 Â FIP1L1-PDGFRA, 1 Â BCR-PDGFRA, 1 Â KIF5B-PDGFRA and 2 Â ETV6-PDGFRB). CSF1R exons were screened in 24 samples with positive or borderline responses, excluding those with known imatinib-responsive mutations, but no further variants were identified. A summary of all mutation screening results is given in Table 2 .
Functional analysis of R106W, R753Q and T952I CSF1R variants
We tested R106W, R753Q and T952I for transforming ability using the colony assay but found that all the three were negative (Figure 4) . Although T952I showed an elevated mean value for colony number/dish, this result is entirely due to the elevated colony growth of a single batch of transfected cells and was not consistently seen in two further transfected cell batches, as is demonstrated by the high standard error of the mean for this construct. Taken together, these results suggest that these three variants may be non-pathogenic passenger mutations or rare polymorphisms.
Discussion
Since the identification of CSF1R as the human cellular homolog of the v-fms oncogene in the Susan McDonough feline sarcoma virus, there has been much interest in the transforming and functional properties of activating CSF1R mutations. In addition to point mutations at L301 and Y969 and C-terminal deletions, which correspond to mutations found in v-fms, additional point mutations within the C-terminal region, 19 the extracellular domain 23 and the kinase activation loop 19 have also been found to be fully or partially transforming. However, despite the identification of point mutations that can activate CSF1R in cellular assays, activating mutations of CSF1R have not been convincingly demonstrated in human leukemias. Early reports of CSF1R mutations in acute myeloid leukemia employed sensitive assays that may have selected for sequence changes in very small subclones. Recently, a RBM6-CSF1R fusion gene resulting from a t(3;5)(p21;q33) translocation was identified in the acute megakaryoblastic cell line MKPL-1, but no fusion-positive patients have been described. 24 Figure 6 CSF1 neutralization inhibits cell growth. GDM1, but not EOL1 or BV173, showed growth inhibition after 3 days of exposure to an anti-CSF1-neutralizing antibody. CSF1, colony-stimulating factor 1. Abbreviations: AML, acute myeloid leukemia; aMPN, atypical myeloproliferative neoplasm; ARMS, amplification refractory mutation system; CSF1R, colony-stimulating factor 1 receptor.
A screen of hemopoietic cell lines for imatinib sensitivity was undertaken with the ultimate aim of identifying novel imatinib gene targets. GDM1, derived from a patient with an acute myelomonocytic transformation of a Philadelphianegative myeloproliferative disorder, 25 showed a markedly reduced proliferation when exposed to imatinib. Mutational analysis of known imatinib targets revealed a missense mutation within exon 12 of CSF1R that results in a Y571D amino-acid change. CSF1R is constitutively phosphorylated in GDM1, and we have shown CSF1R-Y571D to be transforming and constitutively phosphorylated in cell line models.
Y571 is located within the juxtamembrane domain, which is highly conserved among the related class III receptor TKs PDGFRA, PDGFRB, FLT3 and KIT. Interaction of Y571 with a conserved glutamic acid (E576) within the kinase domain is thought to contribute to stabilization of the receptor in an inactive conformation, 26 and its disruption by Y571 phosphorylation contributes to kinase activation. In more distantly related TKs such as the insulin receptor 27 and ephrin B2 28 receptors, the disruption of equivalently placed tyrosines and glutamic acid residues by tyrosine phosphorylation has also been implicated in kinase activation.
A study on the equivalent murine tyrosine (Y569) has placed it within a sequence directing ligand-induced endocytosis. 29 Alanine substitution was shown to result in kinase inactivation although phenylalanine substitution appeared not to alter kinase activity. 29 However, there are no published reports on the activity of aspartic acid substitution as seen in GDM1. In two reports, the alteration of an equivalent tyrosine residue has been shown to be activating: substitution of the equivalent tyrosine with alanine in PDGFRB (Y557) results in constitutive receptor phosphorylation and IL3 independence in Ba/F3 cells; 30 similarly, alanine substitution of an equivalent tyrosine (Y984) in the insulin receptor results in both increased basal phosphorylation and response to insulin. 27 In general, therefore, the association of constitutive kinase activity with CSF1R-Y571D, we have described, is consistent with the current understanding of the role of the juxtamembrane region and therefore shares similarities with other welldescribed activating TK receptor juxtamembrane mutations such as point mutations and tandem duplications in KIT and FLT3. 31 We did not find any CSF1R changes in patients who had been selected for possible imatinib sensitivity based on in vitro assays, and therefore we think it unlikely that CSF1R is mutated in the small number of patients who show imatinib sensitivity of unknown etiology. An extensive mutation screen of CSF1R in primary aMPN patient samples revealed three missense mutations resulting in R106W, R753Q and T952I amino-acid changes in patients whose response to imatinib is unknown. No constitutional material was available and we were therefore not able to confirm that these were acquired changes. However, our transformation assay did not show these changes to be transforming although it remains a possibility that they may be transforming in other systems. It is likely that these are 'passenger' mutations, that is acquired changes without a pathogenic affect, rather than 'driver' mutations. Indeed, a recent high-throughput mutation analysis of TKs followed up by functional analysis 32 has suggested that passenger mutations may be more common than previously thought.
Overall, our results provide the first example of an activating mutation of the CSF1R juxtamembrane region in patient-derived material, but indicate that CSF1R mutations are not a common cause of imatinib sensitivity.
